myelodysplastic syndromes (MDS) | Page 120 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

Perceptions of Disease State, Treatment Outcomes, and Prognosis Among Patients with Myelodysplastic Syndromes: Results From an Internet-Based Survey.

Author(s): 
Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R
Primary Author: 
Sekeres MA
Journal Title: 
Oncologist
Original Publication Date: 
Apr 2011

Bone Marrow Diseases: 

Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for de novo disease.

Author(s): 
Andolina JR, Kletzel M, Tse WT, Jacobsohn DA, Duerst RE, Schneiderman J, Helenowski I, Rademaker A, Chaudhury S
Primary Author: 
Andolina JR
Journal Title: 
Pediatr Transplant
Original Publication Date: 
Feb 2011

Allogeneic hematopoetic stem cell transplantation in pediatric

Bone Marrow Diseases: 

Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates.

Author(s): 
Durairaj S, Chew S, Hyslop A, Keenan N, Groves MJ, Tauro S.
Primary Author: 
Durairaj S
Journal Title: 
Am J Hematol
Original Publication Date: 
May 2011

Consideration of iron-chelation (IC) in transfusion-dependent patients is recommended in most clinical-practice guidelines on myelodysplastic syndromes (MDS). The financial impact of IC on health-care systems is predicted through economic modeling, but an analysis based on actual prevalence is lacking. Here, we have investigated the potential drug-costs and need for IC in a cohort of 189 United Kingdom-based MDS patients diagnosed from 2000 to 2010. Patients with low or intermediate-1 IPSS scores were identified as eligible for IC if ≥24 red

Bone Marrow Diseases: 

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

Author(s): 
Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ.
Primary Author: 
Jädersten M
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2011

PURPOSE To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk

Bone Marrow Diseases: 

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System.

Author(s): 
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E.
Primary Author: 
Schanz J
Journal Title: 
J Clin Oncol
Original Publication Date: 
Apr 2011

PURPOSE The

Bone Marrow Diseases: